375,00 €
1,15 % gestern
L&S, 16. Januar, 22:52 Uhr
ISIN
CH0012032048
Symbol
ROG
Index

Roche Aktie News

AD HOC NEWS
2 Tage alt
Die US-Investmentbank Goldman Sachs hat das Kursziel für Roche CH0012032048 deutlich erhöht von 260 auf 365 Franken und die Aktien von "Sell" auf "Neutral" hochgestuft.
Positiv
Reuters
4 Tage alt
BGI Genomics and Roche Diagnostics have rolled out tests for Alzheimer's disease in China, the companies said, in an effort to expand access to easier-to-use diagnosis and monitoring choices for patients with the brain-wasting condition.
Neutral
Business Wire
27 Tage alt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ (mosunetuzumab-axgb), as a subcutaneous (SC) formulation, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or mor...
Negativ
Reuters
28 Tage alt
Deals between pharmaceutical companies and Washington to reduce prices for medicines in the United States will likely push up the cost of new drugs in Switzerland, the CEO of Swiss pharma giant Roche was quoted as saying on Saturday.
Neutral
WSJ
29 Tage alt
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Positiv
The Guardian
29 Tage alt
Officials pledge ‘massive savings' as companies agree to offer drugs at prices paid in other wealthy countries
Positiv
CNBC
29 Tage alt
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug prices to cheaper ones abroad. Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk have already struck deals with the Trump administration to cut prices.
Neutral
Business Wire
29 Tage alt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced an agreement with the U.S. government that lowers costs for state Medicaid programs, encourages other wealthy countries to reward innovation, and increases opportunities for direct patient access. Under this agreement, Genentech is making commitments that address all four...
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen